Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populations

Basit Öğe Kaydı
dc.authoridUGUR, KADER/0000-0003-4028-2041
dc.authoridAKKOC, Ramazan Fazil/0000-0002-0559-8932
dc.authoridDalkilic, Semih/0000-0002-6892-247X
dc.contributor.authorCelik, Onder
dc.contributor.authorCelik, Nilufer
dc.contributor.authorAydin, Suleyman
dc.contributor.authorBaysal, Bora
dc.contributor.authorAydin, Suna
dc.contributor.authorSaglam, Aylin
dc.contributor.authorGursu, Yagmur
dc.date.accessioned2024-09-18T20:56:50Z
dc.date.available2024-09-18T20:56:50Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIt can be misleading to think that the new severe acute respiratory-syndrome coronavirus (SARS-COV2) which has a very strong mutation and adaptation capabilities, uses only the angiotensin-converting enzyme II (ACE2) pathway to reach target cells. Despite all the precautions taken, the pandemic attack continues and the rapid increase in the number of deaths suggest that this virus has entered the cell through different pathways and caused damage through different mechanisms. The main reason why the ACE2 pathway comes to the fore in all scientific studies is that this receptor is located at the entry point of basic mechanisms that provide alveolo-capillary homeostasis. SARS-CoV-2 has to use nuclear factor-kappa B (NF-kappa B), caveloae, clathrin, lipoxin, senile protease and pro-teasome pathways in addition to ACE2 to enter the target cell and initiate damage. For this reason, while new drug development studies are continuing, in order to be beneficial to patients in their acute period, it is imperative that we are able to come up with drugs that activate or inhibit these pathways and are currently in clinical use. It is also critical that we adopt these new pathways to the treatment of pregnant women affected by SARS-CoV-2, based on the scientific data we use to treat the general population.en_US
dc.identifier.doi10.14715/cmb/2020.66.3.36
dc.identifier.endpage229en_US
dc.identifier.issn0145-5680
dc.identifier.issn1165-158X
dc.identifier.issue3en_US
dc.identifier.pmid32538775en_US
dc.identifier.scopus2-s2.0-85086622598en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage221en_US
dc.identifier.urihttps://doi.org/10.14715/cmb/2020.66.3.36
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12117
dc.identifier.volume66en_US
dc.identifier.wosWOS:000540410000036en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherC M B Assocen_US
dc.relation.ispartofCellular and Molecular Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2en_US
dc.subjectACE2en_US
dc.subjectViral entry pathwaysen_US
dc.subjectNuclear factor-kappa Ben_US
dc.subjectProteasomeen_US
dc.subjectLipoxinen_US
dc.subjectOff label drugsen_US
dc.subjectSerine proteaseen_US
dc.titleCombating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populationsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
4.3 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu